The Efficacy of Risedronate in Prevention of Bone Loss in Patients Receiving High Dose Corticosteroid Treatment
This study has been completed.
Information provided by:
Tuen Mun Hospital
First received: September 5, 2006
Last updated: September 27, 2007
Last verified: September 2007
The efficacy of risedronate in prevention of bone loss in patients receiving high dose corticosteroid treatment
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
Primary Outcome Measures:
Secondary Outcome Measures:
- Adverse events, new vertebral fractures
| Estimated Enrollment:
| Study Start Date:
| Study Completion Date:
We compare the effect of risedronate with placebo in bone mineral density changes in patients receiving high dose corticosteroids for their underlying diseases
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Patients with various medical conditions who require high dose glucocorticoid treatment: (1) pulse methylprednisolone; (2) oral prednisolone (>=0.8mg/kg/day) or equivalent for at least 6 weeks.
- Age>=18 years and <75 years.
- Pregnant or lactating women.
- Uncorrected hypocalcemia.
- History of esophageal stricture.
- Previous intolerance or hypersenstivity to biphosphonates.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00372372
|Tuen Mun Hospital
|Hong Kong, China |
Tuen Mun Hospital
||CC Mok, MD FRCP
||Tuen Mun Hospital, Hong Kong
No publications provided
History of Changes
|Other Study ID Numbers:
|Study First Received:
||September 5, 2006
||September 27, 2007
||Hong Kong: Ethics Committee
Keywords provided by Tuen Mun Hospital:
corticosteroids, bone mineral, risedronate, bisphosphonate
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on March 05, 2014
Bone Diseases, Metabolic
Bone Density Conservation Agents
Physiological Effects of Drugs
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action